

17^e JOURNÉE SCIENTIFIQUE DU GRPSO ET DU GREAT

Groupe de Recherche sur le **PSO**riasis

Groupe de Recherche sur l'**Eczéma AT**opique
DA (Dermatite Atopique)

**VENDREDI
6 OCTOBRE
2023**

ESPACE DU CENTENAIRE
Maison de la RATP - Paris



Sous l'égide de la





Etude DUPECZEMAIN


Dr Marie Tauber M.D PhD

MCU-PH Service d'Allergologie et Immunologie Clinique


Hôpital Lyon Sud

Inserm U1111 CIRI- Inserm U1291 Infinity

L'éczéma chronique des mains (ECM)



Tentatives multiples de classification



Tentatives multiples de classification

Eczéma exogène

Dermatite irritative de contact
Dermatite allergique de Contact
Dermatite de contact aux protéines

Eczéma chronique fissuré

Eczéma récurrent vésiculeux



Eczéma
endogène

Atopique
Hyperkératosique
Récurrent vésiculeux

Eczéma hyperkératosique palmaire

Eczéma interdigital

Pulpites

Eczéma des mains nummulaire



Tentatives multiples de classification


Pas très clair tout ça...



Pas de consensus



Intrication complexe



Irritation

+ Allergie de contact



Atopie



P
S
O
R
I
A
S
I
S

P
A
L
M
A
I
R
E





Dupilumab Treatment in Patients With Atopic Hand and Foot Dermatitis: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

Eric L. Simpson¹, Jonathan I. Silverberg², Margitta Worm³, Golará Honari⁴, Koji Masuda⁵, Ewa Sygula⁶, Jennifer Maloney⁷, Leda P. Mannent⁸, Jing Xiao⁷, Ariane Dubost-Brama⁸, Ashish Bansal⁷

¹Oregon Health & Science University, Portland, OR, USA; ²The George Washington School of Medicine and Health Sciences, Washington, DC, USA; ³Charité-Universitätsmedizin Berlin, Berlin, Germany; ⁴Stanford University School of Medicine, Redwood City, CA, USA; ⁵Kyoto Prefectural University of Medicine, Kyoto, Japan; ⁶Antyżaj Miałecki Memorial Independent Public Clinical Hospital, Katowice, Poland; ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ⁸Sanofi, Chilly-Mazarin, France

Corresponding author

Eric L. Simpson, Oregon Health & Science University, Portland, OR, USA; Email: simpson@ohsu.edu

Disclosures


Simpson E.L.: AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, Regeneron Pharmaceuticals, Inc. – investigator; AbbVie, Boehringer Ingelheim, Dermavant, Eli Lilly, Fortá, Incyte, LEO Pharma, Merck Therapeutics, Pfizer, Pierre Fabre Dermo-Cosmetics, Regeneron Pharmaceuticals, Inc., Sanofi, Valeant – consultant fees. Silverberg J.I.: AbbVie, BMS, Eli Lilly, GSK, Incyte, LEO Pharma, Health Therapeutics, Regeneron Pharmaceuticals, Inc., Roche – investigator; AbbVie, Anacor Pharmaceuticals, Eli Lilly, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, MedImmune, Merck Therapeutics, Pfizer, Procter & Gamble, Reskin Therapeutics, Regeneron Pharmaceuticals, Inc. – consultant; Regeneron Pharmaceuticals, Inc., Sanofi – speaker. Worm M.: AbbVie, Almiral, Boehringer Ingelheim, Bayer, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, Valeant – advisory board and/or consulting fees. Honari G.: Nipera, Regeneron Pharmaceuticals, Inc. – research funding. Masuda K.: Sanofi – speaker. Sygula E.: Nothing to disclose. Maloney J., Xiao J., Bansal A.: Regeneron Pharmaceuticals, Inc. – employees and shareholders. Mannent L.P., Dubost-Brama A.: Sanofi – employees, may hold stock and/or stock options in the company.

Acknowledgments


Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT04117804. Medical writing/editorial assistance was provided by Nigel De Melo, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the [Good Publication Practice guideline](#).

Presented at the 2023 Annual Meeting of the American Academy of Dermatology (AAD), New Orleans, LA, USA, March 17–21, 2023.





DUPECZEMAIN : ESSAI CLINIQUE MULTI-CENTRIQUE FRANCAIS : TOULOUSE – MONTPELLIERS – BORDEAUX – LYON



Essai clinique institutionnel français impliquant 4 centres du GREAT


Critères d'inclusion : adultes – ECM sévère (IGA mains à 3 ou 4) – en échec des dermocorticoïdes

Critère de Jugement Principal : % de diminution du score mTLSS (modified Total Lesion Symptom Score) à S16 Sévérité (de 0 à 3) de 6 signes (érythème, desquamation, lichénification/hyperkératose, vésicules, œdème, fissures) + Intensité (de 0 à 3) de 2 symptômes (prurit et/ou douleur) = score de 0 à 21




Point d'étape

- Inclusions terminées n = 94
- Fin d'étude prévue décembre 2023
- Premiers résultats dans 6 mois




ETUDE TRANSLATIONNELLE




Dos de la main la plus atteinte



ETUDE TRANSLATIONNELLE



ETUDE TRANSLATIONNELLE



Appariement donneurs contrôles








Peau abdomen/ bras n=31

Peau dos de la main n=2


**ONLY
TODAY**

**ANALYSE
TRANSCRIPTOMIQUE
ARN total**





Gènes spécifiques à l'ECM



Cohorte totale de patients (n=17)



Remerciements



Carle Paul
Manon Boussier
Fatma Jendoubi
Marilina Konstantinou
Amel Bouznad
Salama Hegazy
Cristina Livideanu
Audrey Coussegal




Aurélie Du Thanh
Nadia Raison Peyron
Céline Turiaf
Et toute l'équipe
montpelliéraine



Julien Seneschal
Anne-Sophie Darrigade
Brigitte Milpied
Valérie Vuong
Et toute l'équipe
bordelaise



Audrey Nosbaum
Frédéric Bérard
Jean-François Nicolas
Florence Hacard
Anne-Camille Garreau
Louise Jaulent
Mariline Faton
Julia Penot



www.immception.com
www.infinity.inserm.fr

TOULOUSE :
Nicolas GAUDENZIO
Lilian BASSO
Jérémy MARTIN
Nadine SERHAN
Audrey HOUCINE



INSERM U1111
Centre International de
Recherche en Infectiologie

LYON :
Marc VOCANSON
Juliette MOUIREN
Amandine MOSNIER
Perrine GERY

